PedAM
Pediatric Disease Annotations & Medicines
| Disease | hyperglycemia |
| Phenotype | |type 2 diabetes |
| Sentences | 186 |
| PubMedID- 25181406 | The aims of the study were to compare the glycemic control achieved by using sliding-scale or basal-bolus regimens for the management of severe or acute hyperglycemia in patients with type 2 diabetes and to analyze factors associated with the types of insulin therapy used in the management of severe or acute hyperglycemia. |
| PubMedID- 21382648 | [recommendations for the pharmacological treatment of hyperglycemia in type 2 diabetes]. |
| PubMedID- 21256872 | Background: uncontrolled hepatic glucose production (gluconeogenesis), and glycogenolysis, is a major contributor to the fasting hyperglycemia associated with type 2 diabetes. |
| PubMedID- 20577053 | Metformin is widely used to treat hyperglycemia in individuals with type 2 diabetes. |
| PubMedID- 25927597 | In recent years, selective sglt2 inhibitors have been developed and are now in clinical use for the treatment of hyperglycemia in patients with type 2 diabetes mellitus [19]. |
| PubMedID- 24396690 | In 1992, it was first revealed that acute intravenous glp-1 infusion (for 30 or 210 minutes) significantly reduced postprandial hyperglycemia in patients with type 2 diabetes [1,2]. |
| PubMedID- 24790595 | Of great clinical interest, synthetic ligands of pparγ, belonging to the class of thiazolidinediones (tzds), such as troglitazone, pioglitazone, and rosiglitazone, function as insulin sensitizers and are used for treating hyperglycemia in patients with type 2 diabetes [7, 18–20]. |
| PubMedID- 26000636 | The recent combined statement from the american diabetes association and the european association for the study of diabetes on patient-centered approaches to hyperglycemia in patients with type 2 diabetes highlights the importance of shared decision-making that considers all aspects of treatment options, including preferences for benefits and harms [2]. |
| PubMedID- 26287417 | However, auc measurements for hypoglycemia (glucose <3.9 mmol/l) were not statistically significant.a ppb-r-203-based diet reduced postprandial hyperglycemia in patients with type 2 diabetes without increasing the risk of hypoglycemia or glucose excursion. |
| PubMedID- 23704521 | Moreover, the role of hyperglycemia in type 2 diabetes as a determinant of persistent vascular dysfunction remains to be clarified. |
| PubMedID- 26294778 | Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. |
| PubMedID- 26253538 | Secondly, we sought to investigate the effect of glp-1 modulation on myocardial function in the setting of hyperglycemia in patients with type 2 diabetes mellitus (t2dm). |
| PubMedID- 23614630 | The position statement on the management of hyperglycemia in patients with type 2 diabetes mellitus issued in 2012 by the american diabetes association and the european association for the study of diabetes contains significant improvements over the 2009 version, including an emphasis on patient-centered care, enhanced strategies for lifestyle modification, a focus on comprehensive cardiovascular risk reduction, and increased pharmacotherapy choices. |
| PubMedID- 21447652 | Hepatic insulin resistance is defined as the inability of systemic hyperinsulinemia to suppress hgp and contributes to both fasting and postprandial hyperglycemia seen in patients with obesity and type 2 diabetes (7). |
| PubMedID- 26294779 | Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. |
| PubMedID- 22055501 | The role of hyperglycemia in cad associated with type 2 diabetes is less clear. |
| PubMedID- 26207066 | Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. |
| PubMedID- 24695667 | Important early findings in incretin biology include proof-of-concept studies showing glp-1 infusion improves hyperglycemia in patients with type 2 diabetes [3] and cloning of the glp-1r cdna [4]. |
| PubMedID- 21617178 | Because of a mutation in the leptin receptor, bks db/db mice are hyperphagic and obese, develop severe type 2 diabetes with marked hyperglycemia, and serve as an experimental model of type 2 diabetes. |
| PubMedID- 24717767 | Abnormal regulation of glucagon secretion has been implicated in the development of hyperglycemia in patients with type 2 diabetes mellitus [16], and a recent study in animal models indicated that a reduction in glucagon action can have profound effects on mitigating hyperglycemia even in the presence of severe hypoinsulinemia [17]. |
| PubMedID- 23315305 | The clinical management of hyperglycemia in patients with type 2 diabetes mellitus (t2dm) is guided not only by published treatment algorithms, but also by consideration of recent evidence and through consultation with colleagues and experts. |
| PubMedID- 21085649 | However, newer data reveal that hyperketonemia or diabetic ketoacidosis can also co-exist with hyperglycemia in patients with type 2 diabetes [52]. |
| PubMedID- 24735134 | Conclusions: opt2mise will represent the largest studied homogeneous cohort of type 2 diabetes patients with persistent hyperglycemia despite optimized mdi therapy. |
| PubMedID- 22439599 | hyperglycemia in patients with type 2 diabetes places them at significant risk for cardiovascular events and other diabetic complications [2], as shown for example by the united kingdom prospective diabetes study (ukpds 35), which demonstrated a strong association between the risk of diabetic complications and hyperglycemia [3]. |
| PubMedID- 21354306 | hyperglycemia in patients with type 2 diabetes causes multiple neuronal complications, e.g., diabetic polyneuropathy, cognitive decline, and embryonic neural crest defects due to increased apoptosis. |
| PubMedID- 21457068 | Relationship among a1c, hypoglycemia, and hyperglycemia in japanese with type 2 diabetes--results from continuous glucose monitoring data. |
| PubMedID- 24089511 | Glp-1 agonists have been incorporated into standard algorithms to treat hyperglycemia in patients with type 2 diabetes, and while the objective of these treatment regimens is to reduce glycemia safely (2), the importance of specifically targeting postprandial glycemia is increasingly being recognized (3). |
| PubMedID- 25651730 | Umbilical cord mesenchymal stem cell transfusion ameliorated hyperglycemia in patients with type 2 diabetes mellitus. |
| PubMedID- 25633683 | Postprandial hyperglycemia is common in patients with type 2 diabetes (t2dm) [3,4]. |
| PubMedID- 26244639 | Chronic hyperglycemia associated with uncontrolled type 2 diabetes, or an age-related disease will promote increased production of α-dicarbonyl molecular species, including highly reactive mgo. |
| PubMedID- 25742705 | hyperglycemia in type 2 diabetes results from insulin resistance in the peripheral tissues, insulin deficiency due to insufficient pancreatic output, and excessive hepatic glucose output and is associated with serious microvascular and macrovascular complications [1]. |
| PubMedID- 25791371 | It may progress to hyperglycemia, leading to type 2 diabetes. |
| PubMedID- 21521130 | Introduction: in preliminary clinical studies, aleglitazar, a new dual ppar-alpha-gamma agonist, has been demonstrated to improve hyperglycemia and dyslipidemia in patients with type 2 diabetes mellitus. |
| PubMedID- 20398338 | Conclusion: the nile rat fed typical rodent diets develops hyperinsulinemia that precedes hyperglycemia (insulin resistance) leading to diet-induced type 2 diabetes associated with hypertriglyceridemia, hypercholesterolemia, and hypertension. |
| PubMedID- 22996185 | Management of hyperglycemia in type 2 diabetes: a patient-centered approach. |
| PubMedID- 22235198 | The inbred mouse strain kk/ta, established as a diabetic strain in japan, spontaneously exhibits characteristics of type 2 diabetes associated with fasting hyperglycemia, glucose intolerance, hyperinsulinemia, mild obesity, dyslipidemia, and albuminuria. |
| PubMedID- 22496878 | We have recently identified selenoprotein p (sep) as a liver-derived secretory protein that causes insulin resistance and hyperglycemia in patients with type 2 diabetes [1]. |
| PubMedID- 20393151 | Objective: an increase in the rate of gluconeogenesis is largely responsible for the hyperglycemia in individuals with type 2 diabetes, with the antidiabetes action of metformin being thought to be achieved at least in part through suppression of gluconeogenesis. |
| PubMedID- 21163329 | Abnormal hepatic gluconeogenesis contributes significantly to both fasting and non-fasting hyperglycemia of patients with type 2 diabetes. |
| PubMedID- 22619286 | Titled “management of hyperglycemia in type 2 diabetes: a patient-centered approach,” this effort results from a joint request of the ada and easd executive committees and represents the final product of years of work (1). |
| PubMedID- 23700194 | Since the introduction of sitagliptin into the diabetes therapeutic armamentarium in 2006, the use of dipeptidyl peptidase-4 (dpp-4) inhibitors for the management of hyperglycemia in patients with type 2 diabetes has increased worldwide. |
| PubMedID- 23882051 | However, reducing hyperglycemia in individuals with type 2 diabetes has not been clearly associated with a decreased risk of developing cancer (49,50). |
| PubMedID- 20103560 | Recent trials on the prevention of cvd events by the treatment of hyperglycemia in patients with type 2 diabetes have been disappointing. |
| PubMedID- 24358252 | Both insulin resistance and impaired insulin secretion are known to play important roles in the development of hyperglycemia in patients with type 2 diabetes. |
| PubMedID- 22564914 | Elevated hepatic gluconeogenesis is a major contributor to hyperglycemia in type 2 diabetes. |
| PubMedID- 25596527 | Glut4 function is impaired in obesity and type 2 diabetes leading to hyperglycemia and an increased risk of cardiovascular disease and neuropathy. |
| PubMedID- 20484139 | Elevated hgp caused by defective suppression of gluconeogenesis is one of the primary defects contributing to fasting hyperglycemia in patients with type 2 diabetes (2–4). |
| PubMedID- 23649520 | hyperglycemia in patients with type 2 diabetes is resolved shortly after roux-en-y gastric bypass (rygb), suggesting that mechanisms independent of weight loss contribute to the improvement in glycemic control (1–4). |
| PubMedID- 22517736 | Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the american diabetes association (ada) and the european association for the study of diabetes (easd). |
| PubMedID- 24858947 | hyperglycemia resulting from type 2 diabetes mellitus (t2dm) is the main cause of diabetic complications such as retinopathy and neuropathy. |